References
- Ose, L., Luurila, O., Eriksson, J., Olsson, A., Lithell, H. and Widgren, B., on behalf of the Cerivastatin Study Group (1999). Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hyper-cholesterolaemia: a multinational, randomised, double-blind study. Cum Med. Res. Opinion, 15, 228–240.
- Stein, E. A., Schopen, U. and Catagay, M. (1999). A pooled efficacy analysis of cerivastatin in the tretament of primary hyperlipidaemia. Clin. Drug Invest., 18, 433–444.
- Geil, P. B., Anderson, J. W. and Gustafson, N. J. (1995). Women and men with hypercholesterolaemia respond similarly to an American Heart Association Step I Diet. J. Am. Dietet. Assoc., 95, 436–446.
- Assman, G., Schulte, H., von Eckardstein, A. and Huang, Y. (1996). High-density lipoprotein as a predictor for coronary heart disease risk. The PRO CAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis, 124 (Suppl), S11–S20.
- International Task Force for the Prevention of Coronary Heart Disease (1998). Coronary heart disease: reducing the risk. Nutr. Metab. Cardiovasc. Dis., 8, 205–271.
- NCEP Adult Treatment Panel II Report (1993). J. Am. Med. Assoc., 269, 3015–3023.
- Jones, P., Kafonek, S., Laurora, I. and Hunninghake, D. (1998). Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol., 81, 582–587.
- Vaughan, C., Gotto, A. and Basson, C. (2000). The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol., 35, 1–10.